Navigation Links
Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease,Presented at International Congress of Parkinson's Disease and,Movement Disorders

Faust's lead molecule, FP0011, exhibited a differentiated combination of therapeutic effects and good tolerance in mid- to late-stage patients

STRASBOURG, France, June 6, 2007 - Faust Pharmaceuticals S.A., a clinical stage product company specializing in the discovery and development of drugs for diseases of the nervous system, today announced that the Phase IIa clinical trial results of its small molecule glutamate release inhibitor, FP0011, are being presented at the Movement Disorder Society (MDS)'s 11th International Congress of Parkinson's Disease and Movement Disorders, taking place this week in Istanbul, Turkey. The poster, presented by the study's Principal Investigator, Olivier Rascol, M.D., of University Hospital, Toulouse, has been selected for presentation at the Highlights of Posters session during the conference.

In the trial, FP0011 was well tolerated and improved Parkinsonian symptoms as measured by the Unified Parkinson's Disease Rating Scale (UPDRS), as well as motor fluctuations as measured by patient diaries. The compound had positive effects in three critical areas: "core" Parkinsonian motor symptoms (such as tremor, rigidity and akinesia), axial symptoms not sensitive to L-dopa and other commonly-prescribed dopaminergic drugs (such as disturbance of posture, balance and gait), and dyskinesia (i.e. the jerky uncontrolled movements that result as a side effect of long term L-dopa therapy).

The Phase IIa trial was conducted according to an innovative "n of 1" trial design in which a small population (n=8) of mid-to-late stage Parkinsonian patients with L-dopa-induced motor complications were administered FP0011 or placebo over 4 cross-over periods on a randomized, blinded basis.

Professor Rascol, Dr. Joaquim Ferreira (Lisbon), and Dr. Lucette Lacomblez (Paris), were principal investigators in this Phase II trial. The "n of 1" trial design was previously used by Dr. Ferrei
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
2. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Bevacizumab Market ,2010-2019" ... under the trade name of Avastin, bevacizumab injection is ... 2010, it was approved by CFDA to treat metastatic ... China all come from Roche and its ...
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Genomic Health, Inc . (Nasdaq: GHDX ... Executive Chairman of the Board, will present at the Piper ... November 29, 2011 at 1:30 p.m. Eastern Time (ET).   ... of the presentation, visit the Investor Relations section of Genomic ...
... Nov. 22, 2011 Frost & Sullivan honors ... Sullivan 2011 North American Technology Innovation Award in ... VoXcell ® Imaging Suite.  For the first ... throughout the enterprise using robust industry-standard applications, leading-edge ...
Cached Medicine Technology:Genomic Health to Present at the Piper Jaffray Health Care Conference 2Genomic Health to Present at the Piper Jaffray Health Care Conference 3KJAYA Medical Honored with 2011 Frost & Sullivan Award for Technology Innovation in Web-based Medical Imaging Data Management 2
(Date:8/28/2015)... ... ... For Dallas, the time is nearing for the annual Heart Walk, and ... The American Heart Association hosts their well-known Heart Walk to raise money in awareness ... can be made. Walkers can participate in the cause and someone can also donate, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones of a ... struggling with chemical dependency, may be able to find some hope in the ... treatment center for addiction located in Western Michigan. Focusing on several different aspects ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Medical Solutions, ... 2015 Best Places to Work in Healthcare by Modern Healthcare and will ... , Now in its eighth year, the Best Places to Work in Healthcare ...
(Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ground ... the Food and Drug Administration to eliminate submental fat, also known as the double ... among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , Developed ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... is dedicated to distributing health information technology innovation to transform quality and efficiency ... of the survey will be de-identified and aggregated before being publicly shared to ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2
... Nov. 30 Mary Rita Hyland, Assistant Vice President of ... elected to the 2010 Board for the Workgroup for Electronic ... of leadership positions at SSI since joining the organization in ... of the Quality Assurance division and Business Continuity for SSI. ...
... of ,stroke belt, study finds , MONDAY, ... belt" of the southern United States have a lifelong higher ... live elsewhere later, a new study shows. , Data on ... South Carolina, Georgia, Tennessee, Arkansas, Mississippi and Alabama show a ...
... , LOS ANGELES, ... as a woman, and brings with it a host of uncomfortable ... mood swings, weight gain , night sweats and lethargy are ... worse, menopause signs and symptoms can show up a ...
... , ... , NEW YORK, Nov. 30 Distance runners who live at ... races in areas that are at sea level. Can heart failure ... tent-like, high-altitude simulator? , That is the question being studied among 15 heart ...
... Fla., Nov. 30 The launch of Invivo Corporation,s ... FDA-cleared, fully-automated morphological system for the detection and analysis ... system will be officially unveiled at the Radiological Society ... Developed in partnership with leading experts in breast MRI, ...
... safe transplant results in animals , MONDAY, Nov. 30 (HealthDay ... cells from transplanted human-derived umbilical cord blood could help treat ... that such stem cells can differentiate into a long list ... Soon Park of the Samsung Medical Center in Seoul, Korea, ...
Cached Medicine News:Health News:SSI Assistant Vice President Elected to WEDI Board 2Health News:Birth in South Raises Stroke Risk for Life 2Health News:Birth in South Raises Stroke Risk for Life 3Health News:Anti-Aging Institute of California Offers New Natural Solution for Menopause Symptoms 2Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 2Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 3Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 4Health News:New Breast MRI Technology Enables Enhanced Breast Cancer Detection 2Health News:New Breast MRI Technology Enables Enhanced Breast Cancer Detection 3
Microcontroller-based isolated electrosurgical generator, designed for all general purpose surgical procedures. Unit includes: Instant Response technology, adaptive REM system, isolated output, CEM c...
Maddox rod and occluder...
Long handle occluder - White...
Double Ended Occluders...
Medicine Products: